Autologous transplant series for transformed lymphomas (TL).
| Study . | N . | Median follow-up, y . | OS . | PFS/EFS . | TRM, % . |
|---|---|---|---|---|---|
| OS indicates overall survival; PFS, progression-free survival; EFS, event-free survival; TRM, treatment-related mortality; DFS, disease-free survival; N/A: data not available. | |||||
| Williams42 | 50 | 4.9 | 2 y: 64% 5 y: 51% | 5 y PFS: 30% Median PFS: 13 mo | 18 |
| Chen40 | 35 | 4.3 | 5 y: 37% | 5 y PFS: 36% | 20 |
| Ramadan46 | 33 | 1.7 | 2 y: 72% 5 y: 72% | 2 y EFS: 47% 5 y EFS: 33% | 10 |
| Friedberg38 | 27 | 3.0 | 5 y: 58% | 5 y DFS: 46% | 0 |
| Foran45 | 27 | 2.4 | Median: 8.5 y | N/A | 15 |
| Sabloff44 | 23 | 7.6 | 5 y: 56% | 5 y PFS: 25% | 4 |
| Andreadis43 | 22 | 5.5 | Median: 4.6 y | Median EFS: 1.4 y | 4 |
| Study . | N . | Median follow-up, y . | OS . | PFS/EFS . | TRM, % . |
|---|---|---|---|---|---|
| OS indicates overall survival; PFS, progression-free survival; EFS, event-free survival; TRM, treatment-related mortality; DFS, disease-free survival; N/A: data not available. | |||||
| Williams42 | 50 | 4.9 | 2 y: 64% 5 y: 51% | 5 y PFS: 30% Median PFS: 13 mo | 18 |
| Chen40 | 35 | 4.3 | 5 y: 37% | 5 y PFS: 36% | 20 |
| Ramadan46 | 33 | 1.7 | 2 y: 72% 5 y: 72% | 2 y EFS: 47% 5 y EFS: 33% | 10 |
| Friedberg38 | 27 | 3.0 | 5 y: 58% | 5 y DFS: 46% | 0 |
| Foran45 | 27 | 2.4 | Median: 8.5 y | N/A | 15 |
| Sabloff44 | 23 | 7.6 | 5 y: 56% | 5 y PFS: 25% | 4 |
| Andreadis43 | 22 | 5.5 | Median: 4.6 y | Median EFS: 1.4 y | 4 |